Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010
The SB101 and SB102 studies have together dosed 19 subjects to dateThis early review of safety sets the stage for further dose escalationAdditional safety and cytokine-specific data are expected during
United States Michaelv Morabito Pankaj Mohan Richard Kenney Exchange Commission Sonnet Biotherapeutics Inc
Source: finanznachrichten.de